PDCD1 and neoplasm: Pembrolizumab (Keytruda) and nivolumab (Opdivo) are human IgG4 PD-1 immune checkpoint suppressive antibodies [183] that interfere with PD-1 mediated signal transduction and have the ability to reverse T cell functional inhibition, restoring anti-tumour immunity [184].